[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 289,980
  • Shares Outstanding, K 100,339
  • Annual Sales, $ 79,590 K
  • Annual Income, $ -67,590 K
  • EBIT $ -58 M
  • EBITDA $ -38 M
  • 60-Month Beta 2.91
  • Price/Sales 3.48
  • Price/Cash Flow N/A
  • Price/Book 6.74

Options Overview Details

View History
  • Implied Volatility 352.44% (-11.91%)
  • Historical Volatility 56.06%
  • IV Percentile 59%
  • IV Rank 31.55%
  • IV High 1,033.35% on 11/11/25
  • IV Low 38.62% on 02/23/26
  • Expected Move (DTE 9) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.50
  • Today's Volume 15
  • Volume Avg (30-Day) 81
  • Put/Call OI Ratio 0.62
  • Today's Open Interest 331
  • Open Int (30-Day) 430
  • Expected Range 2.94 to 2.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.35 +25.11%
on 08/06/26
2.99 -1.67%
on 08/04/26
-0.05 (-1.67%)
since 07/10/26
3-Month
2.35 +25.11%
on 08/06/26
4.19 -29.83%
on 05/14/26
-1.02 (-25.76%)
since 05/12/26
52-Week
2.35 +25.11%
on 08/06/26
5.48 -46.35%
on 10/16/25
+0.28 (+10.53%)
since 08/12/25

Most Recent Stories

More News
Cellectis Reports Financial Results for the Second Quarter 2026

Lasme-cel: Pivotal Phase 2 in r/r B-ALL (BALLI-01)  FDA RMAT designation received for lasme-cel Full Phase 1 clinical data from the BALLI-01 trial presented at EHA 2026 Pivotal Phase 2 first...

CLLS : 2.99 (+3.46%)
Cellectis to Report Second Quarter Financial Results on August 6, 2026

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

CLLS : 2.99 (+3.46%)
Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

CLLS : 2.99 (+3.46%)
Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...

CLLS : 2.99 (+3.46%)
Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...

CLLS : 2.99 (+3.46%)
Cellectis’ Annual Shareholders General Meeting to be Held on June 25, 2026

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...

CLLS : 2.99 (+3.46%)
Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...

CLLS : 2.99 (+3.46%)
Cellectis Reports Financial Results for the First Quarter 2026

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial)  Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL...

CLLS : 2.99 (+3.46%)
Cellectis to Report First Quarter Financial Results on May 11, 2026

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop...

CLLS : 2.99 (+3.46%)
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...

CLLS : 2.99 (+3.46%)

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

3rd Resistance Point 3.03
2nd Resistance Point 2.96
1st Resistance Point 2.93
Last Price 2.99
1st Support Level 2.83
2nd Support Level 2.76
3rd Support Level 2.73

See More

52-Week High 5.48
Fibonacci 61.8% 4.28
Fibonacci 50% 3.91
Fibonacci 38.2% 3.55
Last Price 2.99
52-Week Low 2.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.